CD38 and Miyoshi myopathy: In MM patients, anti-CD38 therapy is associated with decreased immunoglobulin levels in serum, reduced autoantibody levels, increased frequency of infections, and reduced vaccination responses (to SARS-CoV-2) (8, 9, 11, 12, 13, 14, 15).